3,4-dihydroxybenzohydroxamic acid has been researched along with Multiple Myeloma in 1 studies
Multiple Myeloma: A malignancy of mature PLASMA CELLS engaging in monoclonal immunoglobulin production. It is characterized by hyperglobulinemia, excess Bence-Jones proteins (free monoclonal IMMUNOGLOBULIN LIGHT CHAINS) in the urine, skeletal destruction, bone pain, and fractures. Other features include ANEMIA; HYPERCALCEMIA; and RENAL INSUFFICIENCY.
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (100.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Raje, N | 1 |
| Kumar, S | 1 |
| Hideshima, T | 1 |
| Ishitsuka, K | 1 |
| Yasui, H | 1 |
| Chhetri, S | 1 |
| Vallet, S | 1 |
| Vonescu, E | 1 |
| Shiraishi, N | 1 |
| Kiziltepe, T | 1 |
| Elford, HL | 1 |
| Munshi, NC | 1 |
| Anderson, KC | 1 |
1 other study available for 3,4-dihydroxybenzohydroxamic acid and Multiple Myeloma
| Article | Year |
|---|---|
Didox, a ribonucleotide reductase inhibitor, induces apoptosis and inhibits DNA repair in multiple myeloma cells.
Topics: Antineoplastic Agents; Antineoplastic Agents, Alkylating; Apoptosis; Caspases; Cell Cycle; Cell Surv | 2006 |